X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Allergan Receives Approval for Ozurdex in China for the Treatment of Retinal Vein Occlusion (RVO)

Yuvraj_pawp by Yuvraj_pawp
30th October 2017
in Research & Development

Allergan plc announced that it has received an Imported Drugs License (IDL) from the Chinese FDA to market Ozurdex® (dexamethasone intravitreal implant 0.7 mg) for the treatment of adult patients with macular edema following either Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO).

Ozurdex is the first approved intravitreal injection for RVO in China. Retinal vein occlusion (RVO) is the second most common type of retinal vascular disorder after diabetic retinal disease and one of the most common causes of sudden, painless, unilateral loss of vision.i It is estimated that there are around 7.4 million patients in China with RVO who require treatment. ii,iii,iv

“Ozurdex addresses a clear unmet need in Chinese patients with RVO, a potentially blinding disease if left untreated,” explained David Nicholson, Chief Research and Development Officer at Allergan. “Inflammation is a critical component in RVO leading to macular edema and potential vision loss. Ozurdex suppresses mediators of inflammation and delivers rapid and sustained visual gains.v,vi As the prevalence of eye diseases and blindness grows in Asiavii, we are committed to improving access to innovative medicines and individualised treatments like Ozurdex that provide rapid improvements in visual acuityv and importantly, reduce the burden of injection for patients.”

Ozurdex is a biodegradable implant containing dexamethasone, an anti-inflammatory corticosteroid, in a single use applicator. Following an intravitreal injection into the back of the eye, the implant slowly releases the dexamethasone directly to the retina over a period of several months.viii

“As a result of its clinical performance, Ozurdex was put on the priority approval list by the Chinese Food and Drug Administration (CFDA). The approval of Ozurdex underscores our commitment to bring more innovative eye care solutions to tackle unmet medical needs in China. Coming next, Allergan China will be accelerating access to Ozurdex for Chinese hospitals – and more importantly to Chinese patients,” said Shirley Zhao, Allergan China President.

The clinical efficacy and safety of Ozurdex has been assessed in three phase III randomised, double-masked, sham-controlled studies. Based on the pooled analysis of the two global pivotal studies RVO1 and RVO2 as well as the China registration study RVO3 results, treatment with Ozurdex showed statistically significant improvements in visual gains compared with sham treatment. The most commonly-reported adverse events following treatment with Ozurdex are those frequently observed with ophthalmic steroid treatment or intravitreal injections (elevated IOP, cataract formation and conjunctival or vitreal haemorrhage respectively).vi

Commenting on the announcement, Marc Princen, Allergan International President said, “We are delighted to receive this approval, which means we can now provide RVO patients in China with an effective treatment option. China is a very important market for Allergan; it’s the second largest pharmaceutical market in the world after the US and furthermore has the largest number of people with visual impairment and blindness globally. We are committed to bringing innovative treatments to these patients and help improve their quality of life.”

About retinal vein occlusion (RVO)?
Retinal vein occlusion is the second most common cause of reduced vision due to a retinal vascular disorder; the most common cause is diabetic retinopathy.ix,i It is defined as obstruction of a retinal vein, which causes haemorrhage in the retina. This process eventually leads to macular edema, i.e. thickening of the macular region.x Left untreated, macular edema can result in decreased visual acuity.xi

Retinal vein occlusion occurs when the circulation of the retinal vein becomes blocked by an adjacent blood vessel or thrombosis.xi It can be classified according to the location of the occlusion. BRVO occurs in a branch retinal vein and CRVO occurs in the central retinal vein and involves all four quadrants of the retina.xii BRVO and CRVO have distinct underlying causes, prognoses and outcomes, and commonly require different management strategies. xii

About Allergan plc
Allergan plc , headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercialising branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.

Allergan’s success is powered by our more than 18,000 global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan’s website at www.Allergan.com

 

Previous Post

Enterome completes first phase 1 study of EB8018 to treat Crohn’s disease

Next Post

Eisai To Present Latest Data At 10th Clinical Trials On Alzheimer’s Diesase

Related Posts

News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
News

Report Indicates UK £62bn Behind In Global R&D Investment

3rd November 2022
News

Once More, M&As In Biotechechnology Industry Are Thriving

2nd November 2022
DNA
News

Ancient Viral DNA Guards Against Infections In Human Genome

31st October 2022
News

Omicron Subvariants Withstand Essential Antibody Treatments

31st October 2022
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits
News

Research And Development In UK Falls Behind Other Nations

28th October 2022
Next Post

Eisai To Present Latest Data At 10th Clinical Trials On Alzheimer’s Diesase

Latest News

Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In